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Sir,
We read with interest the article by Das et al. on the value of skin testing and patch testing in determining the cause of cutaneous drug reactions. [1] The authors have rightly pointed out that skin testing (prick test or intradermal tests) should not be done in patients who have had severe cutaneous adverse reactions (SCARs) including Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN), but patch tests may be appropriately advised. However, in clinical practice, we find many patients apprehensive of undergoing further in vivo testing, and in such cases, blood tests (genetic biomarkers) that could explain the SCAR episode appear a reasonable and attractive option as they do not pose a clinical risk. Determining the HLA tissue type (allele) is one such option, and studies have now confirmed strong and significant associations between certain HLA alleles and risk of drug-induced SJS/TEN. [2] We present our experience of four cases of drug-induced SCARs where knowledge of HLA class I and II alleles proved quite useful in clinical management.
HLA ABDR typing was done using PCR method of amplification of sequence-specific primers after DNA was extracted from 200 µL ethylenediaminetetraacetic acid whole blood visualized using gel-based electrophoresis under ultraviolet light. Table 1 outlines the case details including clinical description and HLA profiles of the patients. Patient P1 had a severe clinical course (fever, back pain, extensive exfoliative skin rash, and oral ulcers) within 4 weeks of starting oxcarbazepine and required oral corticosteroids over 3 months to control the adverse drug reaction. HLA typing confirmed the presence of HLA-B*15, with primers amplifying specific to HLA-B*15:02, that is associated with SCAR to carbamazepine and oxcarbazepine. [2, 3] Knowledge of other alleles in the patient such as HLA-A*02 (associated with toxicity to oxicam, a nonsteroidal anti-inflammatory agent), HLA-B*38 (associated with SJS/TEN to sulfamethoxazole, and agranulocytosis to antithyroid drugs), or DRB1*15 (drug-induced liver injury with amoxicillin-clavulanate) helped counsel her against future adverse drug reactions. She remained well on levetiracetam for over a year without any problem. Patients P2 and P3 also had high-risk HLA alleles identified that explained the adverse drug reaction episodes, HLA-B*58 associated with allopurinol toxicity (in P2), and interestingly multiple at-risk HLA alleles (B*15, B*51, A*11 associated with drug hypersensitivity syndrome to carbamazepine) in patient P3. Both P2 and P3 were counseled against possible adverse reactions to other drugs after HLA alleles were identified. Patient P4 was most unusual as she reacted to multiple drugs (multidrug hypersensitivity syndrome, MDHS) while being treated for chronic myeloid leukemia and its complications, and all the drugs that she reacted to had known HLA associations [ Table 1 ]. [4] In conclusion, while tests such as skin prick/intradermal or patch testing can provide information as to whether the drug reaction was due to an IgE-mediated or cell-mediated phenomenon, DNA-based HLA typing can provide genetic risk identification that has exceedingly high sensitivity and specificity for some categories of drugs. For example, routine HLA typing for HLA-B*57:01 testing before highly active antiretroviral therapy initiation has now shown to dramatically reduce severe and fatal adverse reactions to abacavir, [5] pretesting with HLA-B*58:01 to prevent allopurinol-induced SCARs, [6] as well as providing phenotype specificity such as HLA-B*58:01 for allopurinol and B*15:02 is a risk for SJS/TEN to carbamazepine but not DRESS or maculopapular exanthems. [2] However, the information on future risk of drug reactions for most drugs is not complete at this stage, and it remains a clinical decision on use in a medical situation. It is possible that more advanced knowledge of HLA genes will further identify risk factors of the role of viruses in the drug-induced severe adverse reactions.
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